Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Dermatology
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
Andrew Blauvelta Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, USA
https://orcid.org/0000-0002-2633-985X
https://orcid.org/0000-0002-2633-985X, Nianwen Shib Truven Health Analytics, Truven Health Analytics, IBM Watson Health, Cambridge, MA, USAhttps://orcid.org/0000-0002-0596-7566
https://orcid.org/0000-0002-0596-7566, Mwangi J. Muragec Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
https://orcid.org/0000-0003-2769-3188
https://orcid.org/0000-0003-2769-3188, , , Russel Burgec Eli Lilly and Company, Indianapolis, IN, USA;d University of Cincinnati, Cincinnati, OH, USAhttps://orcid.org/0000-0001-7907-6400
https://orcid.org/0000-0001-7907-6400, , , Nicole M. Zimmermanb Truven Health Analytics, Truven Health Analytics, IBM Watson Health, Cambridge, MA, USAhttps://orcid.org/0000-0001-5819-7844
https://orcid.org/0000-0001-5819-7844 & show allRelated Research Data
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
Source:
Taylor & Francis
Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over two years of follow-up in real-world settings
Source:
Taylor & Francis
Linking provided by
